|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 8/64 | (2013.01) |
| A61K 39/08 | (2006.01) | ||
| A61K 8/64 | (2006.01) | ||
| A61K2800/592 | (2013.01) | ||
| A61Q 19/08 | (2006.01) | ||
| A61K2800/91 | (2013.01) | ||
| A61Q 19/08 | (2013.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 11/02 | (2018.01) | ||
| A61P 13/06 | (2018.01) | ||
| A61P 13/10 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 17/02 | (2018.01) | ||
| A61P 17/10 | (2018.01) | ||
| A61P 17/16 | (2018.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 21/02 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 25/02 | (2018.01) | ||
| A61P 25/04 | (2018.01) | ||
| A61P 25/06 | (2018.01) | ||
| A61P 25/08 | (2018.01) | ||
| A61P 25/14 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 37/00 | (2018.01) | ||
| A61P 37/04 | (2018.01) | ||
| A61P 5/00 | (2018.01) |
| (11) | Number of the document | 3332805 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18150826.8 |
| Date of filing the European patent application | 2009-12-28 | |
| (97) | Date of publication of the European application | 2018-06-13 |
| (45) | Date of publication and mention of the grant of the patent | 2022-02-23 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 142063 P | 2008-12-31 | US |
| (72) |
RUEGG, Curtis, L. , US
STONE, Hongran, F. , US
WAUGH, Jacob, M. , US
|
| (73) |
ReVance Therapeutics, Inc. ,
7555 Gateway Blvd., Newark, CA 94560,
US
|
| (54) | INJECTABLE BOTULINUM TOXIN FORMULATIONS |
| INJECTABLE BOTULINUM TOXIN FORMULATIONS |